<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Medina Neergaard | Activity</title>
	<link>https://www.catswannabecats.com/members/canlilac07/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/canlilac07/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Medina Neergaard.</description>
	<lastBuildDate>Sat, 27 Jun 2026 19:00:28 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">c4745f6deca96e5302ac6a4bae8948ba</guid>
				<title>Medina Neergaard posted an update: will support selecting novel agents for neoadjuvant or [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/24360/</link>
				<pubDate>Sun, 08 Jun 2025 12:22:27 -0400</pubDate>

									<content:encoded><![CDATA[<p>will support selecting novel agents for neoadjuvant or adjuvant strategies.</p>
<p>Neoadjuvant MVAC or GC in cT2-T4N0 MIBC patients fit for cisplatin is still recommended based on OS benefit shown in meta-analyses, butreal-world adherence to NAC is low as ~40-50% ofpatients are unfit for cisplatin. The value of neoadjuvant treatment in node-positive&hellip;<span class="activity-read-more" id="activity-read-more-24360"><a href="https://www.catswannabecats.com/activity/p/24360/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e0eda63bac9cced058b3ea89912df385</guid>
				<title>Medina Neergaard posted an update: The need to test anticancer drugs in multiple indications [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/19843/</link>
				<pubDate>Thu, 05 Jun 2025 10:19:33 -0400</pubDate>

									<content:encoded><![CDATA[<p>The need to test anticancer drugs in multiple indications has been addressed by basket trials, which are Phase I or II clinical trials involving multiple tumor subtypes and a single master protocol. Basket trials typically involve few patients per type, making it challenging to rigorously compare responses across types. We describe the use of&hellip;<span class="activity-read-more" id="activity-read-more-19843"><a href="https://www.catswannabecats.com/activity/p/19843/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4da23845c30987bb422096dbdbcb4740</guid>
				<title>Medina Neergaard posted an update: Breathing is regulated by a host of arousal and sleep-wake [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/8852/</link>
				<pubDate>Sat, 31 May 2025 21:46:47 -0400</pubDate>

									<content:encoded><![CDATA[<p>Breathing is regulated by a host of arousal and sleep-wake state-dependent neuromodulators to maintain respiratory homeostasis. Modulators such as acetylcholine, norepinephrine, histamine, serotonin (5-HT), adenosine triphosphate (ATP), substance P, somatostatin, bombesin, orexin, and leptin can serve complementary or off-setting functions&hellip;<span class="activity-read-more" id="activity-read-more-8852"><a href="https://www.catswannabecats.com/activity/p/8852/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f16d5b5a583e59954d3c548986e197e9</guid>
				<title>Medina Neergaard became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/8761/</link>
				<pubDate>Sat, 31 May 2025 21:38:22 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>